Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and Moderna, Inc. (NASDAQ:MRNA) have reached a stipulation in their ongoing ...
Moderna fends off Alnylam US patent lawsuit over COVID shots, for now
Alnylam Pharmaceuticals admitted defeat, for now, in a lawsuit in Delaware federal court that accused Moderna's blockbuster ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is Expected To Breakeven In The Near Future
With the business potentially at an important milestone, we thought we'd take a closer look at Alnylam Pharmaceuticals, ...
Biogen, Alnylam-partnered Camp4 Therapeutics unveils IPO plans
Camp4 Therapeutics Inc., a Cambridge biotech that has already struck deals with Biogen Inc. and Alnylam Pharmaceuticals Inc., ...
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,300 Today
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $1,295.68 today based on a ...
Alnylam : Phase 3 Study Data Support Potential Of Vutrisiran In ATTR Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals Inc. (ALNY) said that new data from the HELIOS-B Phase 3 study of vutrisiran showed that the drug attenuated ...
TCTMD1d
Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM
Two new analyses from HELIOS-B answer important questions, but some uncertainties remain, says Julie Rosenthal.
Alnylam Pharma’s Promising Clinical Data Tempered by Market Factors in Hold Rating Assessment
Michael Ulz, an analyst from Morgan Stanley, maintained the Hold rating on Alnylam Pharma (ALNY – Research Report). The associated price ...
Yahoo Finance5d
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
Alnylam Pharmaceuticals (ALNY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the ...
The Pharma Letter5d
New Alnylam HELIOS-B vutrisiran data presented at HFSA
US RNAi therapeutics company Alnylam Pharmaceuticals has released two new data sets from the HELIOS-B Phase III study of ...
Nasdaq6d
Alnylam : Phase 3 Study Data Support Potential Of Vutrisiran In ATTR Amyloidosis With Cardiomyopathy
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) said that new data from the HELIOS-B Phase 3 study of vutrisiran showed that the drug attenuated measures of disease progression across multiple ...